A wide variety of solid tumors, including urothelial, ovarian, breast, cervical, colon, pancreatic, gastric, melanoma, glioblastoma, non-small cell lung cancer (NSCLC), and hematologic malignancies have been found to express PD-L1 and to a lesser extent PD-L2, which correlate with adverse prognosis (143–149). Here, CD274 is linked to non-small cell lung carcinoma.